home / stock / bctx / bctx quote
Last: | $1.69 |
---|---|
Change Percent: | 1.26% |
Open: | $1.57 |
Close: | $1.69 |
High: | $1.75 |
Low: | $1.53 |
Volume: | 220,159 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.69 | $1.57 | $1.69 | $1.75 | $1.53 | 220,159 | 05-31-2024 |
$1.59 | $1.51 | $1.59 | $1.64 | $1.3701 | 140,691 | 05-30-2024 |
$1.54 | $1.38 | $1.54 | $1.54 | $1.3178 | 169,695 | 05-29-2024 |
$1.37 | $1.45 | $1.37 | $1.45 | $1.35 | 205,564 | 05-28-2024 |
$1.44 | $1.47 | $1.44 | $1.49 | $1.2699 | 1,979,386 | 05-27-2024 |
$1.44 | $1.47 | $1.44 | $1.49 | $1.2699 | 1,979,386 | 05-24-2024 |
$1.43 | $1.5 | $1.43 | $1.5599 | $1.4 | 170,644 | 05-23-2024 |
$1.5 | $1.56 | $1.5 | $1.56 | $1.473 | 73,495 | 05-22-2024 |
$1.49 | $1.59 | $1.49 | $1.625 | $1.47 | 294,927 | 05-21-2024 |
$1.49 | $1.49 | $1.49 | $1.54 | $1.4193 | 268,191 | 05-20-2024 |
$1.39 | $1.47 | $1.39 | $1.49 | $1.33 | 165,184 | 05-17-2024 |
$1.38 | $1.7 | $1.38 | $1.7 | $1.3 | 350,692 | 05-16-2024 |
$1.63 | $2 | $1.63 | $2.0523 | $1.6075 | 301,244 | 05-15-2024 |
$2.11 | $2.18 | $2.11 | $2.2427 | $2.09 | 28,536 | 05-14-2024 |
$2.2304 | $2.25 | $2.2304 | $2.31 | $2.17 | 18,190 | 05-13-2024 |
$2.25 | $2.2401 | $2.25 | $2.31 | $2.23 | 6,158 | 05-10-2024 |
$2.26 | $2.23 | $2.26 | $2.44 | $2.1601 | 58,189 | 05-09-2024 |
$2.24 | $2.252 | $2.24 | $2.3188 | $2.1901 | 12,267 | 05-08-2024 |
$2.19 | $2.24 | $2.19 | $2.28 | $2.19 | 14,572 | 05-07-2024 |
$2.27 | $2.275 | $2.27 | $2.2857 | $2.21 | 11,865 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Corp. Company Name:
BCTX Stock Symbol:
NASDAQ Market:
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq...
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastases M...